Skip to content
Menu

Zeev Bovan

688 posts

Posts (688)

Zeev Bovan TSLA 6 months ago #383

$TARA
Latest on Protara Therapeutics:
The big catalyst today is the updated Phase 2 ADVANCED-2 data for TARA-002 in bladder cancer (NMIBC). The company reported:
72% complete response at any time
67% at 6 months
55% durable response at 12 months
no Grade 3+ treatment-related adverse events reported.
Management says it remains on track to start the registrational ADVANCED-3 study in the second half of 2026.
Earlier this week, the company also reported Q1 2026 earnings:
net loss widened to about $17.8M as R&D spending increased
cash position around $177M
company says runway extends into 2028.
Another important development:
Protara plans a potential BLA filing in 2H 2027 for TARA-002 in lymphatic malformations after FDA interactions.
What investors are likely focused on now:
Whether the bladder cancer durability data continues holding up in larger cohorts.
FDA alignment for the registrational path.
Dilution risk versus the current cash runway.
Upcoming ADVANCED-3 and STARBORN-1 updates later in 2026.
Overall sentiment around the latest release appears positive because biotech investors usually reward:
durable cancer responses,
clean safety,
and a clear registrational pathway.